{"filing":{"accession_number":"0001437749-26-026262","cik":"0000719135","ticker":"APYX","company_name":"Apyx Medical Corp","form":"8-K","filing_date":"2026-08-06","report_date":"2026-08-06","primary_document":"apyx20260602_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/719135/000143774926026262/apyx20260602_8k.htm"},"events":[{"id":25746,"run_id":23366,"accession_number":"0001437749-26-026262","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"summary":"This is a clear earnings release disclosing Q2 2026 financial results for Apyx Medical Corporation. The filing explicitly states under Item 2.02 that the company \"issued a press release reporting on its results of operations for the second quarter ended June 30, 2026,\" with the press release attached as Exhibit 99.1. The disclosure includes detailed financial statements (condensed consolidated statements of operations and balance sheets), revenue by segment and geography, net loss per share, and full-year 2026 guidance reaffirmation—all hallmarks of a quarterly earnings announcement.","company_name":"Apyx Medical Corp","ticker":"APYX","filing_date":"2026-08-06","form":"8-K","submitted_at":null,"items":[{"id":26655,"accession_number":"0001437749-26-026262","item_number":"2.02","item_title":"Results of Operations and Financial Condition","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a clear earnings release disclosing Q2 2026 financial results for Apyx Medical Corporation. The filing explicitly states under Item 2.02 that the company \"issued a press release reporting on its results of operations for the second quarter ended June 30, 2026,\" with the press release attached as Exhibit 99.1. The disclosure includes detailed financial statements (condensed consolidated statements of operations and balance sheets), revenue by segment and geography, net loss per share, and full-year 2026 guidance reaffirmation—all hallmarks of a quarterly earnings announcement.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T02:30:39.760563+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":26655,"accession_number":"0001437749-26-026262","item_number":"2.02","item_title":"Results of Operations and Financial Condition","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a clear earnings release disclosing Q2 2026 financial results for Apyx Medical Corporation. The filing explicitly states under Item 2.02 that the company \"issued a press release reporting on its results of operations for the second quarter ended June 30, 2026,\" with the press release attached as Exhibit 99.1. The disclosure includes detailed financial statements (condensed consolidated statements of operations and balance sheets), revenue by segment and geography, net loss per share, and full-year 2026 guidance reaffirmation—all hallmarks of a quarterly earnings announcement.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T02:30:39.760563+00:00","company_name":"Apyx Medical Corp","ticker":"APYX","filing_date":"2026-08-06"}]}